Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently recruiting participants for a Phase 3 study titled, ‘A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight.’ The primary goal is to prove that maridebart cafraglutide is more effective than a placebo in reducing body weight among adults who are overweight or obese but do not have Type 2 Diabetes.
The study is testing maridebart cafraglutide, a drug administered subcutaneously, in various doses. The aim is to assess its effectiveness in weight reduction compared to a placebo.
This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor investigators know who receives the treatment or placebo, ensuring unbiased results. The primary purpose is treatment-focused.
The study began on March 12, 2025, with the last update submitted on July 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This clinical update could influence Amgen’s stock performance positively if the results show significant efficacy in weight reduction, potentially boosting investor confidence. It also places Amgen in a competitive position within the weight management pharmaceutical market.
The study is ongoing, with further details available on the ClinicalTrials portal.